SNDL Q3: Record C$20M Free Cash Flow, C$52M Cannabis Impairment, Strategic Review Launched
SNDL is trading near its 52-week low of $1.13 (15% above the low) on light trading volume (0.4× avg).
Summary
SNDL's Q3 filing confirms record C$20.0M free cash flow and positive adjusted operating income, alongside a C$52M non-cash cannabis goodwill impairment and a newly launched strategic review of Cannabis Operations. It also details the Parallel stake step-up to ~92% and AGCO resolution terms.
Key Events · Earnings and Guidance · SNDL
-
Q3 Loss Driven by Non-Cash Impairment
Net loss of C$50.8M versus C$13.3M a year earlier, almost entirely a C$52.0M non-cash goodwill impairment in Cannabis Operations. Adjusted operating income turned positive at C$5.2M, a C$14.8M year-over-year improvement.
-
Record C$20M Quarterly Free Cash Flow
Free cash flow reached a record C$20.0M, up 19.5% year over year, including a C$10.6M benefit from unwinding the captive insurance arrangement. Net revenue was C$238.0M, down 2.5%.
-
Cannabis Operations Strategic Review Launched
Management initiated a strategic review of the segment, weighing asset divestitures through larger productivity initiatives, after a 27.7% revenue decline and a >30% workforce cut at the Kelowna facility.
-
Parallel Stake Rises to ~92%
SNDL's indirect equity interest in Parallel increased from ~67% to ~92% through the rights offering; SunStream's debt ownership rose from 39.4% to 69.4%. SNDL is evaluating direct ownership and consolidation of qualifying U.S. medical cannabis operations.
Analysis · SNDL · Life Sciences
The headline numbers were already out, but this filing carries the substance behind them. Cannabis Operations is now formally under strategic review — divestitures are on the table — after a C$52M non-cash goodwill impairment dragged the quarter to a C$50.8M net loss. Against that, retail delivered record margins, free cash flow hit a record C$20.0M, and the balance sheet holds C$617.8M of cash and investments with no debt. Two structural items change the story: the Parallel stake step-up to ~92% and the AGCO resolution terms ($200,000 penalty, Ontario deconsolidation). The buyback remains the capital-return lever: 23.1M shares retired YTD leaves 243.3M outstanding, and the pending C$50M SIB could cut that by more than another 10%.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.7% of the 1698 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNDL was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $318.7M. The 52-week trading range was $1.13 to $2.34. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.